Effect of diabetes and aminoguanidine therapy on renal adbeen shown to inhibit advanced glycation end-product vanced glycation end-product binding.
I]-AGEof glycated Hb (HbA1c) [4] . Advanced glycation end- 
processes, particularly in the pathogenesis of diabetic
Results. Low-affinity binding sites specific for AGEs in the complications and aging [5] . they may act as receptors and may lead to alterations in Emulsion autoradiography revealed that binding was localized cell function [6, 7] . A number of AGE-binding proteins primarily to proximal tubules in the renal cortex. Renal AGE have been identified. These include a 35 kDa receptor, levels, as assessed by fluorescence or by radioimmunoassay, were increased after three weeks of diabetes. This increase was known as RAGE, which is a member of the immunoglobattenuated by AG therapy.
ulin superfamily [8, 9] . Another AGE-binding protein is
Conclusions. AGE binding sites are present within the proxa lactoferrin-like molecule that is noncovalently associimal tubules of the kidney and appear to be modulated by ated with RAGE. At least four other AGE-binding proendogenous AGE levels. It remains to be determined if these teins have been identified, including OST-40, 80K-H, Gabinding sites represent receptors involved in clearance of lectin 3 [10] , and the antibacterial protein lysozyme [11] .
AGEs or are linked to pathogenic pathways that lead to the development of diabetic nephropathy.
This study has evaluated AGE binding sites in the kidney, a site of diabetic complications that appears to involve AGE-dependent pathways [2, 12] , using both in vitro and in vivo autoradiographic techniques. Furthermore, Advanced glycation is the nonenzymatic and irreversthe effects of diabetes and of AG therapy, maneuvers ible glycation of proteins and lipids [1] . The pathway for associated with changes in endogenous AGE levels [13] , nonenzymatic glycation begins with the interaction of on [ 125 I]-AGE binding were also assessed. To assess the glucose and biological proteins and is most prevalent in relationship between AGE accumulation and [ 125 I]-AGE proteins with a long half-life. Aminoguanidine (AG) has binding in the kidney, AGE levels were simultaneously measured in the kidney.
were randomized into four groups: control, control with buffer made up of 10 mm HEPES, 100 mm NaCl, 5 mm KCl, 5 mm MgCl 2 , 1 mm EGTA, and 0.5 mg/ml bacitracin. AG (2 g/liter in drinking water; Regis, Morton Grove, IL, USA), diabetic (induced by intravenous injection of strepSections were dried at room temperature and were then placed under x-ray film for two weeks. Competitive bindtozocin 50 mg/kg after an overnight fast), and diabetic with AG (1 g/liter in drinking water). Rats were sacrificed after ing studies were performed with varying concentrations of unlabeled AGEs. Competition studies were also perthree weeks. Prior to sacrifice, rats were weighed, and blood pressure was determined by tail cuff plethysmography formed with nonglycated proteins. Nonspecific binding (NSB) was determined by the addition of 10 m unlabeled [15] . Only rats with plasma glucose of more than 15 mmol/ liter were considered diabetic. For in vitro autoradiograAGEs (ϫ200 tracer concentration). Data were obtained from two sections of five different kidneys for each experiphy, kidneys were removed and snap frozen in liquid nitrogen, and 20 m sections were cut on a cryostat and mental point and are shown as mean Ϯ sem. In a separate series of experiments, cryostat sections were incubated mounted on slides coated with gelatin (0.5%). For in vivo autoradiography experiments, animals were infused with with a different radioligand, [ 125 I]-AGE-RNase, and competition studies were performed with unlabeled AGEradiolabeled AGEs before sacrifice (discussed later here).
RNase, AGE-BSA, and native (nonglycated) BSA and Preparation of advanced glycation end-products RNase. Fraktion V, free fatty acid (FFA), bovine serum albuEmulsion autoradiography min (BSA; Boehringer-Mannheim, Mannheim, Germany), or ribonuclease A (RNase) (Sigma Pharmaceuticals, St.
To localize AGE-binding sites, emulsion autoradiography was performed. Following postincubation washLouis, MO, USA) was glycated in vitro by incubation at 37ЊC for 120 days with 0.5 m glucose in 0.2 m sodium ing, sections were fixed at 4ЊC for 30 minutes in 10% neutral-buffered formalin (NBF). Sections were briefly phosphate buffer. The solutions were sterilized by passage through a 0.2 mm millipore membrane filter into a dipped at 42ЊC in LM-1 liquid emulsion (Amersham, Bucks, UK) diluted 1:1 with distilled water, dried for vacuette (vacuum sealed sterile test tube). This filtering step results in the removal of lower molecular weight one to two hours at 25ЊC in less than 80% humidity. The emulsions were then exposed for at least two weeks at substances, including free glucose.
4ЊC before development. Sections were then stained with Iodination of advanced glycation end-products hematoxylin and eosin. Thirty micrograms of AGE-BSA or AGE-RNase were
In vivo autoradiography iodinated using iodogen (1,3,4,6-tetrachloro-3␣,6␣-diphenyl-glycouril; Pierce Chemical Co., Rockford, IL, USA).
To define further cellular localization of [ 125 I]-AGE binding in the renal cortex, the tracer was infused in vivo The mixture was allowed to react for 10 minutes. The entire mixture was removed from the iodogen-coated in separate groups of rats. This approach has been used when characterizing other binding sites because it is assotube and was then added to 200 ml of 0.2% phosphatebuffered gelatin (PBG) [0.2% gelatin into phosphateciated with better preservation of morphology [16, 17] . Rats were anesthetized with pentobarbital sodium (Nembuffered saline (PBS)]. The mixture, including the labeled protein, was separated in a previously prepared butal 50 mg/kg body wt), and the abdominal cavity was opened with a midline incision. BSA in 1 ml of 0.1 m PBS at pH 7.4. After 20 minutes of circulation, the rats were perfused at systolic blood in a preincubation buffer containing 10 mm N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES), 100
pressure (approximately 140 mm Hg) with PBS for one minute, followed by 2% glutaraldehyde for two minutes. mm NaCl, 5 mm KCl, 5 mm MgCl 2 , 1 mm ethyleneglycolbis-(␤-amino-ethyl ether) N, NЈ-tetra acetic acid (EGTA), After perfusion fixation, one kidney was removed and fixed in 10% neutral-buffered formalin overnight before 0.1% BSA, and 0.5 mg/ml bacitracin. Tissue sections were then incubated for three hours in incubation buffer, being embedded in paraffin. Nonspecific binding (NSB) was performed in separate animals by infusion of excess which was made of prewash buffer and [
125 I]-AGE tracer. Final counts in the incubation buffer were approximately (10 Ϫ5 m) unlabeled AGE proteins three minutes prior to the infusion of the [ 125 I]-AGE tracer. The procedure 350 to 400 cpm/l, with the total counts used being approximately 3.0 ϫ 10 6 cpm and a final concentration of was then followed as mentioned earlier here. The other kidney was frozen, and 20 m sections were cut on a approximately 2 pm of [
125 I]-AGE. Tissue sections were washed first in preincubation buffer for four minutes, cryostat, then dried, and placed under x-ray film. Paraffin-embedded sections were cut at 4 m and were followed by two four-minute washes in postincubation Precipitation of proteins was carried out by an addition tions were stained with lectin from phaseolus vulgaris of 8% polyethylene glycol. The minimum detectable con-(PHA-E, red kidney bean) [18] , which specifically stains centration of AGE-RNase was 250 ng/ml, and the closing proximal tubules [19] . Sections were dewaxed through volume (CV) for this assay was 12.3% (N ϭ 21) at a to double-distilled water, were then quenched with methconcentration of 2000 ng AGE-RNase/mg protein. Raanol for 20 minutes, and were washed three times with dioactivity was measured using a gamma counter (Can-PBS. Endogenous sites were blocked by incubation with berra Packard Instruments, St. Louis, MO, USA), and normal horse serum for 10 minutes. Tissue sections were the amount of AGEs present was expressed as ng AGEthen exposed to lectin (1 g/ml) for 60 minutes. SecondRNase. To determine the epitope reacting with our antiary avidin-biotin complex (ABC) staining was then used body, competition studies were performed as previously with 3,3Ј-diaminobenzidine tetrahydrochloride (DAB) described [20] . These experiments indicated that the antito localize lectin binding.
body detects advanced glycated RNase, advanced glycated BSA, and carboxy methyl lysine (CML)-containing Measurement of advanced glycation end-products proteins, including CML-BSA and CML-collagen. HowAs previously described [2] , in parallel experiments ever, the antibody does not detect native BSA, native using the same protocol, the cortex of the left kidney RNase, or pentosidine. was removed, minced, and suspended in PBS, followed
Analysis of results by centrifugation at 15,000 revolutions/min for 30 minutes at 4ЊC. Lipid extraction was performed by the addiAll data are shown as mean Ϯ sem. The density of tion of 5 ml of chloroform/methanol (2:1 vol:vol), foltracer binding was quantitated and analyzed by a comlowed by gentle shaking and overnight incubation at 4ЊC.
puter-aided image analysis system (Imaging Research, The upper layer was removed, and the pellet was washed St. Catherines, Ontario, Canada). Because of the focal three times with methanol and distilled water. The pellet nature of [ 125 I]-AGE binding in the renal cortex, the was then resuspended in 0.05 m acetic acid and 1 mg/ml mean of 20 to 25 quantitations was used for each kidney pepsin, incubated for 18 hours at 4ЊC to remove noncolsection. The B max , which represents binding site density, lagenous proteins, and washed with 0.1 m CaCl 2 , 0.02 m and dissociation constant (K d ), which reflects the affinity Tris-HCl (pH 7.6), and 0.05% toluene. Following digesof the ligand to the receptor, were assessed by the comtion with type IV collagenase (0.1 mg/ml; Sigma) and puter program LIGAND [21] . The program SIGMAproteinase K (0.1 mg/ml; Sigma) for 72 hours at 37ЊC, PLOT was used to determine the value for the half maxithe samples were centrifuged at 15,000 revolutions/min mal inhibitory concentration (IC 50 ). Data were analyzed for 30 minutes at 4ЊC. The resulting supernatant was by analysis of variance on a Macintosh personal comthen used to measure AGE levels.
puter (Apple, Cupertino, CA, USA) using the StatView Advanced glycation end-product levels in collagenase program (Abacus Concepts Inc., Berkeley, CA, USA). A extracted renal homogenates were measured by specific P value of less than 0.05 was considered to be statistically fluorescence (370 nm/440 nm ex/em) as previously designificant. scribed [2] and by a radioimmunoassay (RIA) developed in our laboratory using an antibody directed against AGE-RESULTS BSA [20] . Recent studies have revealed that this antibody Characteristics of animals detects the nonfluorescent AGE, carboxy methyl lysinecontaining proteins [20] . AGE-RNase was used for prepaDiabetes was associated with a reduced weight gain and a marked increase in plasma glucose levels ( Table 1) . ration of tracer and standards. Collagenase-extracted re-Blood pressure was modestly elevated in the diabetic in proximal tubules (Fig. 5 A, (Fig. 6B ). This increase in AGEs in the diabetic medulla, and papilla (Fig. 1) 125 I]-AGE diabetic kidney, there was no significant change in bindbinding after three weeks, particularly in the renal cortex ing affinity. In this study, using both fluorescence and an (Figs. 1C and 3A) . However, there was no difference in RIA, which detects CML-containing proteins, it could the distribution of binding in the renal cortex, medulla, be clearly demonstrated that within three weeks of inor papilla between diabetic and control rats. Aminoguaniduction of experimental diabetes that there is an increase dine treatment did not influence [
125 I]-AGE binding in in AGE levels in the kidney that did not occur with AG control rats but prevented the increase in [
125 I]-AGE bindtreatment. The concurrent increase in AGE levels and ing in diabetic rats (Fig. 3) . A similar pattern of binding AGE binding is consistent with the hypothesis that enwas observed in the renal medulla (Figs. 1D and 3B in the kidney in experimental diabetes. Indeed, in blood a prevention of this increase by AG treatment (Fig. 3B) . vessels, it has been shown that increased expression of Analysis by the computer program LIGAND© re-AGE proteins, as seen in diabetes, is associated with vealed that there was an increase in the B max in diabetes increased levels of the AGE receptor RAGE [22] . (Fig. 3) sorbed by proximal tubules. Therefore, it could be conBy in vitro emulsion autoradiography, it was confirmed sidered that AGE binding observed after in vivo injecthat the major renal cortical binding site was to tubules tion represents nonspecific uptake by proximal tubular in all groups studied, (Fig. 4) . The binding appeared to cells. However, a similar pattern of distribution of the be to proximal tubules. Therefore, to further localize radioligand was observed in the in vitro autoradiographic [
125 I]-AGE binding in the cortex more accurately, in vivo studies, and included repeated washes in buffer to disautoradiography was performed, supplemented by counplace endogenous ligands and proximal tubular enzymes terstaining with lectin from vaseolus vulgaris, which speinvolved in nonspecific protein reabsorption by renal cifically stains proximal tubules. In vivo binding revealed proximal tubular cells. In the in vivo as well as the in an almost threefold increase in renal cortex [
I]-AGE
vitro studies, excess unlabeled AGEs were associated binding in diabetes (control, 565 Ϯ 50; diabetic, 1448 Ϯ with greater than 80% displacement of the radioligand, 56 dpm/mm 2 , P Ͻ 0.01 vs. control). Furthermore, using emulsion autoradiography, the major site of binding was a phenomenon not observed with the native protein. Although this study identified a renal proximal tubular binding site in the kidney, it is difficult to determine if this site represents one of the previously characterized receptors or binding proteins for AGEs. Our own group has localized the receptor for AGEs known as RAGE in the kidney using immunohistochemical techniques [24] . It is unlikely that the binding site characterized in the current study is RAGE, because RAGE is localized primarily to distal tubules and to a lesser extent glomeruli rather than to proximal tubules.
In this study, diabetes was associated with increased AGE binding. A preliminary report has suggested that RAGE mRNA levels may be increased in experimental diabetes mellitus [25] . However, a recent report has sug- known as AGE-R1, AGE-R2, and AGE-R3 [10, 27] , and AGE-R2 and AGE-R3 have been reported to be increased in mesangial cells from the NOD mouse model
The assessment of the binding isotherms revealed that of diabetes [28] . There are no reports of these receptors the AGE binding site was of low affinity, with a K d in being present in proximal tubular cells. Over the last few the nanomolar range. This is consistent with the binding years, several other AGE-binding proteins have been characteristics that have been described for RAGE, as identified, including lactoferrin and lysozyme [11, 29] .
well as for several of the other cloned AGE binding sites Of particular interest is the possibility that the proximal [9, 27, 30] . However, one must be cautious in comparing tubular binding may represent AGEs binding to lysothe findings from in vitro autoradiographic studies to zyme. Further studies are warranted to explore the possithose using membrane-binding techniques. For example, bility that the AGE-binding site identified in this study may represent one of the receptors described earlier here.
the assessment of binding sites in the brain for the pan-of AGEs are manifest early in experimental diabetes mellitus [32, 33] . There was a tendency for the increase in AGEs in the diabetic kidney to be greater, as assessed by RIA when compared with fluorescence measurements (Fig. 6 ). It should be noted that the RIA used in this study also detects CML [20] , a nonfluorescent AGE [34] . Therefore, it is possible that CML-containing AGEs are increased earlier than fluorescent, cross-linked AGEs in response to chronic hyperglycemia in experimental diabetes. Further studies are required to characterize the chemical structure of the various AGEs formed in vivo that are detected by the different assay methods. It is difficult to determine if the AGE binding site described in this study represents a clearance mechanism or a pathway leading to tissue injury. Gugliucci and Bendayan have suggested that the localization of AGE peptides in the proximal tubular cells is increased in diabetes and may lead to tubulointerstitial fibrosis [23] . More recently, it has been shown that one of the AGEs that circulates is localized to proximal tubules of rat kidney [35] . These findings provide further evidence that AGEs, including pentosidine, are reabsorbed by the proximal tubules of the kidney, degraded or modified, and finally excreted in the urine.
It has been demonstrated that AGEs can activate a range of intracellular second messengers, including mitogen-activated protein kinase in a renal tubular cell line [36] . This is consistent with the possibility that tubular cells respond to AGEs and result in a cascade of intracellular events, including expression of cytokines such as the prosclerotic growth factor transforming growth factor-␤ (TGF-␤). Indeed, TGF-␤ has been shown to be induced by exogenous AGEs [37] and in endogenous states of increased AGEs such as experimental diabetes mellitus [14] . Tubulointerstitial fibrosis is a well-known pathological feature occurring in association with glomerulosclerosis in diabetic nephropathy [38] . intracellular processes, including activation of cytokines, that could cause tissue injury [39] [40] [41] [42] . Our group has previously shown that AG can retard the development of experimental diabetic nephropathy [2] . In this study, creatic hormone, amylin, revealed significant differences in the calculated affinity between membrane binding and AG treatment was associated with reduced AGE binding in the kidney. If one assumes that this renal proximal in vitro auotradiographic studies [31] .
In this study, AGEs were already elevated within three tubular binding site is involved in mediating tissue injury, one could speculate that the renoprotective effects of weeks of experimental diabetes mellitus. A similar early rise in AGE levels was reported by our group in vessels AG may involve reduced expression of receptors, which are mediating pathways relevant to the genesis of diafrom diabetic rats using the same RIA as well as by immunohistochemistry [14, 24] . This suggests that AGEs betic complications. The role of AG in mediating renoprotection in diabetes remains under clinical investigathat are either fluorescent or CML-containing appear early after the induction of diabetes mellitus. Hill et al tion [12] . Furthermore, a range of new inhibitors of advanced glycation is now under development, including have reported accumulation of AGEs in skeletal muscle arterioles within four to six weeks of experimental diabenovel inhibitors of AGE formation [43] and cross-link breakers that cleave preformed cross-links [44] . tes [32] . Furthermore, it has been shown that the effects It cannot be excluded that the increase in AGE bindin AGE clearance or in mediating potentially damaging ing in diabetes represents a response to the increase in effects on the kidney relevant to the genesis of diabetic circulating and local AGE levels observed with chronic nephropathy. hyperglycemia. One could speculate that the increase in AGE binding represents a protective mechanism, acti-ACKNOWLEDGMENTS vated in response to AGE formation, that operates in the The work from these studies was financially supported by grants diabetic kidney to clear potentially pathogenetic AGE from the Juvenile Diabetes Foundation International, the National proteins. Therefore, it remains to be determined if the 
